On September 27, the award ceremony of EY Fudan Most Potential Enterprise 2024 and the seminar on high-growth enterprises were held in Shanghai.
Beijing Sungen Biomedical Technology Co., Ltd. (Sungen Biomedical), an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068), was awarded as "EY Fudan's Most Potential Seed Enterprise 2024". Professor Zhiwei Sun, general manager of Sungen Biomedical, was invited to attend the award ceremony.
Professor Zhiwei Sun, general manager of Sungen Biomedical, said that Sungen Biomedical was selected and ranked on the list of "most potential enterprises", which was a high affirmation of the development potential of Sungen Biomedical.
SGC001 is a monoclonal antibody indicated for emergency treatment of acute myocardial infarction (AMI). The drug is developed by Sungen Biomedical, in collaboration with Professor Jie Du's team from Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University. Preclinical pharmacodynamic and toxicological studies reveals that SGC001 has obvious therapeutic effects on heart failure and pathological remodeling of the heart after AMI, with significantly decreased mortality rate, reduced infarction size, improved cardiac functions, good efficacy and a reliable therapeutic window. SGC001 has the potential to become a first-in-class drug, providing safer and more effective therapies for AMI patients worldwide.
Till now, there is no antibody therapy for AMI approved for clinical or commercial stage. The successful clinical trial application in China and the US is an important milestone of SGC001 and a huge step towards the internationalization of innovative drugs developed by Sungen Biomedical.
"Ernst & Young Fudan Most Promising Enterprise Award" is jointly held by Ernst & Young, one of the world's leading four international accounting firms, and Fudan University School of Management, a top professional university in China. Adhering to the principles of professionalism, objectivity and openness, and based on a series of key indicators such as industry attributes, development modes and innovation capabilities, the award is committed to identifying Chinese emerging enterprises with excellent performance, healthy growth, high quality and great development potential, and helping them to enter the world stage.
Updated: Oct 22, 2024
